Athenex Inc (NASDAQ:ATNX) has earned an average broker rating score of 2.00 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. Athenex’s rating score has declined by 33.3% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.
Brokers have set a 12 month consensus target price of $25.73 for the company, according to Zacks. Zacks has also given Athenex an industry rank of 116 out of 265 based on the ratings given to related companies.
A number of research firms have issued reports on ATNX. JPMorgan Chase & Co. began coverage on Athenex in a research note on Wednesday, October 18th. They set a “neutral” rating and a $22.20 price target for the company. Laidlaw began coverage on Athenex in a research note on Tuesday, September 19th. They set a “buy” rating and a $36.00 price target for the company. Credit Suisse Group began coverage on Athenex in a research note on Monday, September 18th. They set an “outperform” rating and a $25.00 price target for the company. Finally, Royal Bank of Canada began coverage on Athenex in a research note on Thursday, September 14th. They set an “outperform” rating and a $35.00 price target for the company.
Shares of Athenex (NASDAQ ATNX) opened at $15.87 on Wednesday. The stock has a market capitalization of $920.38 and a PE ratio of -5.75. Athenex has a 52 week low of $11.21 and a 52 week high of $20.79.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.